Navigation Links
Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
Date:10/20/2013

BOSTON PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity, was approved in August 2011 by the U.S. Food and Drug Administration for the treatment of patients who have these lung cancers. Although robust responses to crizotinib are observed for lung cancers harboring ALK gene abnormalities, the majority eventually become resistant to the effects of the drug. In many cases, resistance arises because of genetic mutations in ALK.

"Resistance to targeted therapies such as crizotinib is a major challenge when treating patients with cancer," said Tod Smeal, Ph.D., associate research fellow in the Oncology Research Unit at Pfizer Inc. in San Diego, Calif. "Our goal is to take advantage of everything we have learned about designing drugs that target kinases like ALK and the ways in which lung cancers become resistant to crizotinib to develop the best next-generation ALK inhibitor we can.

"Our preclinical studies suggest that we are making progress toward achieving our goal: PF-06463922 has potent ALK-inhibiting activity, it is capable of inhibiting all the crizotinib-resistant ALK mutants so far detected in patients, and it can efficiently access the brain. We are excited about these preclinical results and very hopeful that they will translate into meaningful responses in the clinic."

After carefully designing PF-06463922, Smeal and colleagues first showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... ... provide payment parity for an expanded list of telehealth services available to Medicare ... from Representatives Gregg Harper (R-MS 3), Diane Black (R-TN 6) and Peter Welch ...
(Date:7/7/2015)... ... July 07, 2015 , ... The ... a mark on the cosmetic surgery industry with its commitment, teamwork, and dedication ... VisitandCare.com partnered medical provider is committed to patient safety, world-class results, and compassionate ...
(Date:7/7/2015)... York, NY (PRWEB) , ... July 07, 2015 , ... ... thing that can help pass those long, stressful days at work is knowing that ... aren’t always as laid back and stress free as imagined. Planning for a vacation ...
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers for ... of Massachusetts , and the Multicultural AIDS Coalition $3.78 million for a ... have sex with men (MSM) and transgender women, the groups at highest risk ...
(Date:7/7/2015)... ... July 07, 2015 , ... SC&H Group, a leading audit, tax, ... give back to the community through company-wide volunteering efforts. , On an annual basis, ... day to assisting those in need throughout Baltimore and Washington D.C. , ...
Breaking Medicine News(10 mins):Health News:The American Telemedicine Association Supports Legislation to Expand Medicare Coverage for Telemedicine Services 2Health News:Top Plastic Surgery Provider in Brazil Joins VisitandCare.com 2Health News:Top Plastic Surgery Provider in Brazil Joins VisitandCare.com 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:SC&H Group Celebrates 9th Annual Day of Service 2
... international group of eating disorders say that the ... disorders is like blaming// parents for diabetes or ... statements by fashion model Gisele Bundchen stating that ... and further stigmatize eating disorders. ...
... than a dozen people have taken ill and have been ... ‘false’ and ‘ baseless’ by spokesman Xiong Yuanda of the ... was no infectious ‘unknown’ disease, doing the rounds in the ... the Health bureau has sought to dispel reports carried by ...
... AIDS Healthcare Foundation on Monday is expected to file ... pharmaceutical company Pfizer//. The decision is the outcome for ... Viagra in advertisements, Reuters reports. ,According to ... increased risky sexual behavior, as well as cases of ...
... Kochi: In its efforts to promote Kerala as an ideal destination ... shows in the US, Britain, Dubai, Muscat, Kuwait, Sri Lanka and ... because it has to be systematic and we have asked the ... of the policy and when we announce it shortly we would ...
... in the Sydney CBD is linked to the Royal Automobile ... However, they could not confirm the link. ,Seven ... belonging to the Legionella family, Legionella pneumophilia, have been reported ... the Circular Quay area on New Year's Eve. ...
... University and pediatric specialists at Baylor College of Medicine have ... as passkeys that allows drugs to enter cancer cells. ... of the journal Organic and Biomolecular Chemistry. ,All ... Cell walls, or membranes, form a protective cocoon around the ...
Cached Medicine News:Health News:'Families' - Doesn’t Cause Anorexia Nervos 2Health News:'Families' - Doesn’t Cause Anorexia Nervos 3Health News:AIDS Healthcare Foundation to File Lawsuit Against Pfizer 2Health News:Buckyballs Used as 'Passkey' into Cancer Cells 2
(Date:7/7/2015)... Research and ... of the "Biomedical Photoacoustic Imaging Patent ... This patent landscape focuses on photoacoustic ... safe, non-invasive, non-ionizing imaging technique. The technique ... alternative to traditional medical imaging approaches. The ...
(Date:7/7/2015)... VIEJO, Calif. , July 7, 2015 /PRNewswire/ ... company focused on developing innovative devices for the ... R. Michael Kleine has joined its Board ... over 25 years of medical device and healthcare ... biomedical companies where he has commercialized numerous leading-edge ...
(Date:7/7/2015)... Accelovance, Inc. (Accelovance), a global contract ... General Medicine announced the completion of enrollment and ... Therapeutics, Inc. for the Phase 3 trial of ... SUSTOL® (granisetron injection, extended release) as part of ... receptor antagonist fosaprepitant and IV corticosteroid dexamethasone ...
Breaking Medicine Technology:Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 2Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 3Sequent Medical Appoints Mike Kleine to its Board of Directors 2Sequent Medical Appoints Mike Kleine to its Board of Directors 3Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2
... , CHAPEL HILL, N.C., Nov. 25 ... chief executive officer, will present at the Piper Jaffray 21st ... 2009, at The New York Palace Hotel in New York ... company,s two leading antibiotic clinical programs for the treatment of ...
... , FRAMINGHAM, Mass. and SYDNEY, Nov. 25 HeartWare International, ... and provider of less invasive, miniaturized circulatory support technologies revolutionizing ... is scheduled to make an investor presentation at the 21st ... on Wednesday, December 2, 2009. The conference is being held ...
Cached Medicine Technology:HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: